Suicidality and Antidepressant Drugs
Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of protriptyline hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Protriptyline hydrochloride is not approved for use in pediatric patients. (See WARNINGS, Clinical Worsening and Suicide Risk; PRECAUTIONS, Information for Patients; and PRECAUTIONS, Pediatric Use)
Protriptyline hydrochloride is an antidepressant agent.
Protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients.
Media Articles Related to Vivactil (Protriptyline)
Antidepressants Worsen Sexual Dysfunction and Depression?
Source: Medscape Psychiatry & Mental Health Headlines [2016.10.20]
Currently available antidepressants that lead to sexual problems may make depression worse, results of a new survey show.
Medscape Medical News
Depression's physical source discovered; potential for new treatments
Source: Depression News From Medical News Today [2016.10.20]
Understanding of the physical root of depression has been advanced, thanks to research by the University of Warwick, UK, and Fudan University, China.
Depression could be treated with anti-inflammatory drugs
Source: Clinical Trials / Drug Trials News From Medical News Today [2016.10.18]
A new meta-analysis finds a new class of drugs used to treat inflammation in autoimmune diseases may also be an effective treatment for depression.
Final Word? Placebo Response in Depression Trials Not Rising
Source: Medscape Psychiatry & Mental Health Headlines [2016.10.17]
Contrary to popular belief, placebo response rates in antidepressant treatment trials are not rising and have held steady for more than 2 decades, a new study suggests.
Medscape Medical News
Are Some Blood Pressure Meds Linked to Depression, Bipolar Risk?
Source: MedicineNet Bipolar Disorder Specialty [2016.10.12]
Title: Are Some Blood Pressure Meds Linked to Depression, Bipolar Risk?
Category: Health News
Created: 10/11/2016 12:00:00 AM
Last Editorial Review: 10/12/2016 12:00:00 AM
Published Studies Related to Vivactil (Protriptyline)
Effect of protriptyline, 10 mg daily, on chronic hypoxaemia in chronic obstructive pulmonary disease. [1995.03]
A daily dose of 20 mg of protriptyline can improve daytime arterial blood gas tensions in chronic obstructive pulmonary disease (COPD)... Despite the low dose, anticholinergic side-effects occurred in most patients.
The use of protriptyline for respiratory failure in patients with chronic airflow limitation. [1990.07]
Treatment of nocturnal hypoventilation in patients with restrictive chest wall disease and respiratory failure, results in improved daytime arterial blood gas tensions, increase in functional ability and longer survival. Success has been achieved with the use of protriptyline which reduces the duration of rapid eye movement (REM) sleep during which nocturnal hypoventilation occurs.
Effect of protriptyline on ventilatory responses to hypercapnia and asphyxia in normal subjects. [1989.09]
A double-blind crossover study was undertaken to assess the effect of protriptyline on ventilatory responses in normal subjects. Seven subjects received in random order placebo, 10 mg and 20 mg protriptyline daily for 2 weeks... Mean HCVR and HVR following 10 mg and 20 mg protriptyline did not differ significantly from measurements on placebo, neither for the single dose study or after 2 weeks.
Role of protriptyline and acetazolamide in the sleep apnea/hypopnea syndrome. [1988.10]
The role of drug therapy in the treatment of the sleep apnea/hypopnea syndrome is unclear. In a randomised, double-blind, placebo-controlled study, we investigated the value of 14-day therapy with protriptyline (20 mg daily) or acetazolamide (250 mg 4 times per day) on symptoms and on the frequency of apneas, hypopneas, arousals, and 4% desaturations in 10 patients with obstructive sleep apnea/hypopnea syndrome.
Protriptyline, chronic tension-type headaches, and weight loss in women. [1997.07]
Twenty-five women with chronic tension-type headaches were treated with protriptyline for 3 months, with attention paid to days of monthly headaches before and while taking the medication, as well as change in weight and side effects. One patient stopped the medication because of side effects and 2 did not return for follow-up, yielding 22 patients...
Clinical Trials Related to Vivactil (Protriptyline)
Bioequivalency Study of Protriptyline 10 mg Tablets Under Fasted Conditions [Completed]
The objective of this study was to prove the bioequivalence of Protriptyline 10 mg tablets
under fasted conditions
Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism [Completed]
Reduction of volume of the hippocampus has been associated with major depression in many
studies. It has been suggested that antidepressants may protect against hippocampus volume
loss in humans associated with multiple episodes of depression and may also reverse the
reduction of volume caused by the depression. In addition, genetic markers for serotonin are
implicated with depression, and may be an indication of reduced response to antidepressant
This study aims to enroll patients who are defined as having treatment resistant depression
(no remission after at least 2 treatments trials with an antidepressant). They will receive
an MRI scan at the initial visit and either 6 months after sustained remission or 12 months
after they enter the study for non-remitters. They will also be asked to give a blood sample
for genotyping. They will be matched by age and handedness to healthy volunteers with no
personal history of depression who will also receive an MRI scan and genotyping.
The first aim is to compare hippocampal volume of depressed subjects to healthy controls. It
is anticipated that subjects will initially have smaller hippocampal volume but of those who
sustain remission, there will be a small increase in hippocampal volume. It is also
anticipated that specific genetic markers will be related to individuals response to
Page last updated: 2016-10-20